Dubroff: A look ahead after a spectacular November for stock market
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Arbitrator awards $155M in PennyMac dispute
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Portfolio watch
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
AeroVironment crushes expectations but stock still falls
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Sutter Health sees expenses rise in the third quarter
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Banc of California closes merger with PacWest, raises $400M
Los Angeles-based Banc of California announced the completion of its all-stock merger with PacWest Bancorp, which will take effect Dec. 1. Announced on Nov. 30, Pacific Western Bank, a subsidiary of PacWest Bancorp, has now merged into Banc of California meaning the combined bank will operate under the Banc of California name and brand. The Read More →
Acelyrin shares decline after programming error disclosure
Conejo Valley-based Acelyrin saw shares plummet more than 30% on Nov. 28 after the biotechnology startup announced an error in one of its trials for its main treatment. Acelyrin, which is a part of Westlake Village BioPartners investing portfolio, disclosed there was a programming error in a drug trial of izokibep, a treatment for psoriatic Read More →
